Laing R, Coles C, Chambers S, Frampton C, Jennings L, Karalus N, Mills G, Town G I
Canterbury Respiratory Research Group, New Zealand.
Intern Med J. 2004 Mar;34(3):91-7. doi: 10.1111/j.1444-0903.2004.00544.x.
To identify variation in the management of -community-acquired pneumonia between two New Zealand hospitals and the factors that may account for any differences.
A 12-month, prospective two-centre study was conducted. Between July 1999 and July 2000, 474 adult patients with community-acquired pneumonia were enrolled: 304 in Christchurch Hospital and 170 in Waikato Hospital. The patients were similar in age, sex, prior antibiotic use and comorbidity. There was no significant difference in the clinical outcomes for the patients at the two centres.
The mean duration of i.v. antibiotic therapy was 1.7 versus 3.0 days (P < 0.001) and length of stay (LOS) was 3.0 versus 5.9 days (P < 0.001) for Waikato and Christchurch Hospitals, respectively. Using multivariate analysis, we could account for 61% of the observed variation in LOS. Duration of i.v. antibiotic therapy independently accounted for 16% of variation in LOS compared with age (2%), chronic obstructive pulmonary disease, duration of fever, intensive care unit admission and centre of admission (all <1%). For the duration of i.v. antibiotics, centre of admission, largely reflecting clinician practice at each centre, independently accounted for 13% of variation, compared with duration of fever (5%), admission to the Intensive Care Unit (4%), Pneumonia Severity Index score (3%) and bacteraemia (3%).
Of the identifiable factors, variations in clinician behaviour outweighed the influence of patient factors on the duration of i.v. antibiotic therapy, which in turn was the major determinant of LOS for patients hospitalised with community-acquired pneumonia. An early switch from i.v. to oral antibiotic therapy in conjunction with early discharge planning may significantly reduce LOS without compromising patient outcomes.
确定新西兰两家医院在社区获得性肺炎管理方面的差异以及可能导致这些差异的因素。
进行了一项为期12个月的前瞻性双中心研究。在1999年7月至2000年7月期间,纳入了474例社区获得性肺炎成年患者:克赖斯特彻奇医院304例,怀卡托医院170例。患者在年龄、性别、既往抗生素使用情况和合并症方面相似。两个中心患者的临床结局无显著差异。
怀卡托医院和克赖斯特彻奇医院静脉抗生素治疗的平均持续时间分别为1.7天和3.0天(P<0.001),住院时间分别为3.0天和5.9天(P<0.001)。通过多变量分析,我们可以解释观察到的住院时间差异的61%。与年龄(2%)、慢性阻塞性肺疾病、发热持续时间、重症监护病房入住情况和入院中心(均<1%)相比,静脉抗生素治疗持续时间独立解释了住院时间差异的16%。对于静脉抗生素治疗持续时间,入院中心在很大程度上反映了每个中心的临床医生实践,独立解释了13%的差异,而发热持续时间(5%)、入住重症监护病房(4%)、肺炎严重程度指数评分(3%)和菌血症(3%)的解释比例较低。
在可识别的因素中,临床医生行为的差异对静脉抗生素治疗持续时间的影响超过了患者因素,而静脉抗生素治疗持续时间又是社区获得性肺炎住院患者住院时间的主要决定因素。早期从静脉抗生素治疗改为口服抗生素治疗并结合早期出院计划,可能在不影响患者结局的情况下显著缩短住院时间。